

Roman Hajek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/935824/publications.pdf>

Version: 2024-02-01

470
papers

29,324
citations

12330

69
h-index

5988

160
g-index

495
all docs

495
docs citations

495
times ranked

18973
citing authors

#	ARTICLE	IF	CITATIONS
1	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <scp>IKEMA</scp> subgroup analysis. American Journal of Hematology, 2023, 98, .	4.1	6
2	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia, 2022, 36, 288-291.	7.2	23
3	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
4	Third dose of COVIDâ€19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. British Journal of Haematology, 2022, 197, 302-305.	2.5	21
5	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematology, the, 2022, 9, e98-e110.	4.6	32
6	Successful early use of antiâ€SARSâ€CoVâ€2 monoclonal neutralizing antibodies in SARSâ€CoVâ€2 infected hematological patients â€ A Czech multicenter experience. Hematological Oncology, 2022, 40, 280-286.	1.7	19
7	Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. American Journal of Hematology, 2022, , .	4.1	2
8	Efficacy and tolerability of <scp>onceâ€weekly</scp> selinexor, bortezomib, and dexamethasone in comparison with standard <scp>twiceâ€weekly</scp> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <scp>BOSTON</scp> study. American Journal of Hematology, 2022, 97, .	4.1	7
9	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer Journal, 2022, 12, 60.	6.2	2
10	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the <scp>CANDOR</scp> study. British Journal of Haematology, 2022, 198, 988-993.	2.5	5
11	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Advances, 2022, 6, 4506-4515.	5.2	4
12	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica, 2021, 106, 601-604.	3.5	2
13	Focus on monoclonal antibodies targeting Bâ€cell maturation antigen (BCMA) in multiple myeloma: update 2021. British Journal of Haematology, 2021, 193, 705-722.	2.5	18
14	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	10.7	46
15	Reduced alpha diversity of the oral microbiome correlates with short progressionâ€free survival in patients with relapsed/refractory multiple myeloma treated with ixazomibâ€based therapy (AGMT MM 1,) Tj ETQq11k0.784334 rgBT (O		
16	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	7.2	79
17	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. Blood Reviews, 2021, 46, 100758.	5.7	8
18	Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer, 2021, 21, 73.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021, 11, 40.	6.2	46
20	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. <i>Blood Cancer Journal</i> , 2021, 11, 24.	6.2	77
21	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
22	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
23	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 309-322.	1.2	316
24	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	6.2	7
25	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. <i>Cells</i> , 2021, 10, 967.	4.1	9
26	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
27	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	7.0	7
28	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	1.8	21
29	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) – Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8037-8037.	1.6	4
30	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8034-8034.	1.6	1
31	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
32	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	6.2	31
33	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
34	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. <i>European Journal of Haematology</i> , 2021, 107, 466-474.	2.2	1
35	Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort. <i>Transfusion</i> , 2021, 61, 2430-2438.	1.6	2
36	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E383-E386.	4.1	7

#	ARTICLE	IF	CITATIONS
37	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	3.5	22
38	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.1	15
39	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2499-2512.	2.4	11
40	Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 3717.	2.4	5
41	Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2021, 12, 733890.	3.5	9
42	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
43	Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. <i>British Journal of Haematology</i> , 2021, 195, 95-107.	2.5	6
44	Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. <i>Blood Advances</i> , 2021, , .	5.2	3
45	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	2.7	45
46	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. <i>Haematologica</i> , 2021, 106, 1496-1499.	3.5	9
47	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11470.	4.1	6
48	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	4.6	46
49	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	2.5	8
50	Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis. <i>Blood</i> , 2021, 138, 4719-4719.	1.4	0
51	B Cell Transcriptional Coactivator <i>POU2AF1</i> (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication. <i>Blood</i> , 2021, 138, 2670-2670.	1.4	2
52	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. <i>Blood</i> , 2021, 138, 153-153.	1.4	6
53	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. <i>Blood</i> , 2021, 138, 2716-2716.	1.4	1
54	Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2764-2764.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6
56	Natural Killer Cells in the Malignant Niche of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 816499.	4.8	14
57	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
58	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. <i>Leukemia and Lymphoma</i> , 2020, 61, 377-386.	1.3	14
59	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020, 34, 589-603.	7.2	41
60	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16
61	Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. <i>European Journal of Health Economics</i> , 2020, 21, 219-233.	2.8	7
62	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. <i>Leukemia</i> , 2020, 34, 1187-1191.	7.2	13
63	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
64	Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 190-197.	2.2	23
65	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>European Journal of Haematology</i> , 2020, 104, 435-442.	2.2	12
66	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
67	Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. <i>Targeted Oncology</i> , 2020, 15, 599-611.	3.6	12
68	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
69	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , 2020, 10, e034209.	1.9	3
70	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
71	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	1.6	102
72	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	4.1	17

#	ARTICLE	IF	CITATIONS
73	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	13.7	188
74	A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. <i>Cancers</i> , 2020, 12, 1333.	3.7	9
75	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	6.2	16
76	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	2.2	34
77	Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. <i>British Journal of Haematology</i> , 2020, 190, 189-197.	2.5	13
78	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	1.8	4
79	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e629-e644.	0.4	1
80	Intercellular Mitochondrial Transfer in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 1787.	3.7	25
81	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 375-392.	2.2	5
82	Monoclonal antibodies in the treatment of AL amyloidosis: co-targeting the plasma cell clone and amyloid deposits. <i>British Journal of Haematology</i> , 2020, 189, 228-238.	2.5	19
83	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e456-e468.	4.6	244
84	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	1.0	8
85	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
86	Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort. <i>Hematological Oncology</i> , 2020, 38, 412-414.	1.7	11
87	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	7.2	109
88	Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 45-46.	1.4	7
89	ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. <i>Blood</i> , 2020, 136, 9-10.	1.4	15
90	Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone. <i>Blood</i> , 2020, 136, 43-44.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	1
92	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. <i>Blood</i> , 2020, 136, 42-44.	1.4	4
93	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	3
94	Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 17-18.	1.4	3
95	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
96	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. <i>Blood</i> , 2020, 136, 7-8.	1.4	15
97	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 53-54.	1.4	13
98	Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). <i>Blood</i> , 2020, 136, 46-48.	1.4	4
99	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	1.4	3
100	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	1.4	12
101	Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First-Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. <i>Blood</i> , 2020, 136, 26-26.	1.4	13
102	Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. <i>Blood</i> , 2020, 136, 32-34.	1.4	3
103	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8501-8501.	1.6	21
104	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	1.7	5
105	Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data. <i>Neoplasma</i> , 2020, 67, 178-184.	1.6	2
106	Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 8044-8044.	1.6	0
107	Osteolytic bone lesions, hypercalcemia and paraprotein, but not a myeloma: case report and review of literature. <i>Vnitřní Lekarství</i> , 2020, 66, 316-321.	0.2	2
108	Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience. <i>Blood</i> , 2020, 136, 6-7.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
110	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020, 136, 48-50.	1.4	0
111	Exploring <i>POU2AF1</i> (<i>BOB-1</i>) D<i>ependency and Transcription Addiction in Multiple Myeloma. <i>Blood</i> , 2020, 136, 49-49.	1.4	0
112	Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
113	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 40-42.	1.4	0
114	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. <i>Blood</i> , 2020, 136, 39-41.	1.4	1
115	Multiple myeloma in patients up to 30Âyears of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	1.3	13
116	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	1.3	23
117	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2019, 187, 447-458.	2.5	7
118	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	3.7	7
119	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
120	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. <i>Oncology and Therapy</i> , 2019, 7, 141-157.	2.6	3
121	Ixazomibâ€“Thalidomideâ€“Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	6.4	17
122	Long Non-Coding RNAs in Multiple Myeloma. <i>Non-coding RNA</i> , 2019, 5, 13.	2.6	29
123	Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. <i>MDM Policy and Practice</i> , 2019, 4, 238146831881425.	0.9	8
124	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
125	Extramedullary disease in multiple myeloma â€“ controversies and future directions. <i>Blood Reviews</i> , 2019, 36, 32-39.	5.7	66
126	Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?. <i>Disease Markers</i> , 2019, 2019, 1-6.	1.3	4

#	ARTICLE	IF	CITATIONS
127	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	1.4	94
128	Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Neoplasma</i> , 2019, 66, 499-505.	1.6	4
129	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	6.2	32
130	Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. <i>Leukemia</i> , 2019, 33, 1817-1821.	7.2	14
131	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
132	PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US. <i>HemaSphere</i> , 2019, 3, 652-653.	2.7	1
133	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	3.5	18
134	Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. <i>Journal of Cancer</i> , 2019, 10, 5041-5048.	2.5	9
135	A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e4-e5.	0.4	0
136	HDAC8 Mediates Homologous Recombination and Cytoskeleton Integrity in Myeloma with Potential Impact on Cell Growth and Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e127-e128.	0.4	0
137	Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e177-e178.	0.4	0
138	Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e180-e181.	0.4	0
139	Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e293.	0.4	0
140	Real-world comparison of ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e271-e272.	0.4	1
141	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. <i>HemaSphere</i> , 2019, 3, 616.	2.7	1
142	Registry of Monoclonal Gammopathies (RMG) - the monitored real-world database of the Czech Myeloma Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e324-e325.	0.4	0
143	Cytarabine+G-CSF is more effective than cyclophosphamide+G-CSF as a stem cell mobilization regimen in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1107-1114.	2.4	10
144	Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). <i>American Journal of Hematology</i> , 2019, 94, E35-E37.	4.1	35

#	ARTICLE	IF	CITATIONS
145	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
146	Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis. <i>Annals of Hematology</i> , 2019, 98, 951-962.	1.8	2
147	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
148	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 3163-3163.	1.4	4
149	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	1.4	12
150	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	1.4	18
151	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. <i>Blood</i> , 2019, 134, 1887-1887.	1.4	12
152	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. <i>Blood</i> , 2019, 134, 1845-1845.	1.4	2
153	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2019, 134, 3139-3139.	1.4	2
154	Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8000-8000.	1.6	25
155	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 279-283.	0.6	10
156	Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104). , 2019, , .		0
157	The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone. <i>Blood</i> , 2019, 134, 5832-5832.	1.4	0
158	Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. <i>Journal of Clinical Pathology</i> , 2018, 71, 687-694.	2.0	11
159	Venetoclax: A new wave in hematooncology. <i>Experimental Hematology</i> , 2018, 61, 10-25.	0.4	73
160	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. <i>European Journal of Haematology</i> , 2018, 101, 220-236.	2.2	15
161	MRS. , 2018, , .		2
162	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41

#	ARTICLE	IF	CITATIONS
163	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
164	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e219-e240.	0.4	16
165	Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 775-783.	1.9	11
166	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
167	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
168	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2431.	4.8	85
169	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.	6.2	81
170	The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. <i>Anticancer Research</i> , 2018, 38, 5087-5092.	1.1	6
171	Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S248-S249.	0.4	0
172	A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S247-S248.	0.4	1
173	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , 2018, 2, 1633-1644.	5.2	66
174	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018, 103, 1518-1526.	3.5	18
175	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e299-e309.	4.6	41
176	Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Cancer Medicine</i> , 2018, 7, 4132-4145.	2.8	6
177	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	7.2	81
178	Long Non-Coding RNAs in Multiple Myeloma. <i>Genes</i> , 2018, 9, 69.	2.4	22
179	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0202045.	2.5	40
180	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67

#	ARTICLE	IF	CITATIONS
181	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.4	9
182	Sepsis and septic shock. <i>Lancet, The</i> , 2018, 392, 75-87.	13.7	1,205
183	LYMRIT 37-01: A Phase I/II Study of ¹⁷⁷ Lu-Lilotomab Satetraxetan (Betalutin [®]) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) – Analysis with 6-Month Follow-up. <i>Blood</i> , 2018, 132, 2879-2879.	1.4	11
184	Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 1959-1959.	1.4	4
185	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Blood</i> , 2018, 132, 301-301.	1.4	9
186	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrrmm; First Report on Phase 1 Data. <i>Blood</i> , 2018, 132, 1967-1967.	1.4	2
187	Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination. <i>Blood</i> , 2018, 132, 245-245.	1.4	5
188	Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2018, 132, 1971-1971.	1.4	5
189	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	1.4	3
190	Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, e20049-e20049.	1.6	0
191	CD38 targeted treatment for multiple myeloma. <i>Vnitřní Lekarství</i> , 2018, 64, 939-948.	0.2	10
192	Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients:Ā, Analysis from Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2018, 132, 2019-2019.	1.4	0
193	CD38Ātargeted treatment for multiple myeloma. <i>Vnitřní Lekarství</i> , 2018, 64, 939-948.	0.2	3
194	Activity of aldehyde dehydrogenase in BĀcell and plasma cell subsets of monoclonal gammopathy patients and healthy donors. <i>European Journal of Haematology</i> , 2017, 98, 19-25.	2.2	4
195	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. <i>Leukemia</i> , 2017, 31, 115-122.	7.2	61
196	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 2089-2100.	1.3	12
197	Korean medicine clinical practice guideline for lumbar herniated intervertebral disc in adults: An evidence based approach. <i>European Journal of Integrative Medicine</i> , 2017, 9, 18-26.	1.7	15
198	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58

#	ARTICLE	IF	CITATIONS
199	Carfilzomibâ€“lenalidomideâ€“dexamethasone vs lenalidomideâ€“dexamethasone in relapsed multiple myeloma by previous treatment. <i>Blood Cancer Journal</i> , 2017, 7, e554-e554.	6.2	54
200	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2017, 99, 80-90.	2.2	7
201	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45
202	Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. <i>Leukemia</i> , 2017, 31, 2630-2641.	7.2	19
203	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	1.2	619
204	Deregulated expression of long nonâ€“coding <sc>RNA UCA</sc>1 in multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 223-233.	2.2	40
205	The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. <i>Haematologica</i> , 2017, 102, 1617-1625.	3.5	71
206	Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. <i>Journal of Clinical Pathology</i> , 2017, 70, 847-853.	2.0	4
207	Effects of singleâ€“agent bortezomib as postâ€“transplant consolidation therapy on multiple myelomaâ€“related bone disease: a randomized phase <sc>II</sc> study. <i>British Journal of Haematology</i> , 2017, 178, 61-71.	2.5	12
208	Genomewide association study on monoclonal gammopathy of unknown significance (MGUS). <i>European Journal of Haematology</i> , 2017, 99, 70-79.	2.2	16
209	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
210	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	1.3	22
211	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. <i>Leukemia</i> , 2017, 31, 1727-1734.	7.2	41
212	Carfilzomibâ€“dexamethasone vs bortezomibâ€“dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. <i>Leukemia</i> , 2017, 31, 1368-1374.	7.2	50
213	Current applications of multiparameter flow cytometry in plasma cell disorders. <i>Blood Cancer Journal</i> , 2017, 7, e617-e617.	6.2	45
214	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	10.7	320
215	WaldenstrÃ¶mâ€™s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. <i>European Journal of Haematology</i> , 2017, 99, 469-478.	2.2	6
216	<sc>PD</sc>â€“1/<sc>PD</sc>â€“1 inhibitors in haematological malignancies: update 2017. <i>Immunology</i> , 2017, 152, 357-371.	4.4	108

#	ARTICLE	IF	CITATIONS
217	Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e26-e27.	0.4	27
218	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e9.	0.4	0
219	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	7.2	98
220	Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. <i>Hematological Oncology</i> , 2017, 35, 408-419.	1.7	10
221	High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. <i>PLoS ONE</i> , 2017, 12, e0181487.	2.5	10
222	Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. <i>Blood</i> , 2017, 130, 901-901.	1.4	7
223	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (Dvd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8006-8006.	1.6	18
224	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8011-8011.	1.6	15
225	Epidemiology of Multiple Myeloma in the Czech Republic. <i>Klinicka Onkologie</i> , 2017, 30, 2S35-2S42.	0.3	15
226	Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation. <i>Klinicka Onkologie</i> , 2017, 30, 2S43-2S50.	0.3	5
227	Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 56243-56254.	1.8	15
228	Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry. <i>Klinicka Onkologie</i> , 2017, 30, 2S21-2S28.	0.3	4
229	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	4.1	40
230	Cytogenetics in multiple myeloma patients progressing into extramedullary disease. <i>European Journal of Haematology</i> , 2016, 97, 93-100.	2.2	37
231	Adjusted Comparison of Daratumumab Monotherapy Versus Real-World Historical Control Data From The Czech Republic in Heavily Pre-Treated and Highly Refractory Multiple Myeloma Patients. <i>Value in Health</i> , 2016, 19, A711.	0.3	0
232	Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 150.	4.4	18
233	Influence of barrier material and barrier shape on blast wave mitigation. <i>Construction and Building Materials</i> , 2016, 120, 54-64.	7.2	39
234	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861

#	ARTICLE	IF	CITATIONS
235	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
236	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
237	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
238	Long-Term Outcomes and Treatment Patterns in Patients with Symptomatic Multiple Myeloma in the Real-World Setting: A Retrospective Analysis of the Czech Rmg Registry. <i>Value in Health</i> , 2016, 19, A158.	0.3	2
239	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
240	PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. <i>Oncotarget</i> , 2016, 5, e1254856.	4.6	35
241	Multicenter patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. <i>European Journal of Haematology</i> , 2016, 96, 119-127.	2.2	8
242	Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. <i>Gene</i> , 2016, 591, 490-498.	2.2	6
243	Genomewide profiling of copy number alteration in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2016, 97, 568-575.	2.2	24
244	Immunomodulatory drugs in AL amyloidosis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 249-260.	4.4	24
245	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , 2016, 17, 27-38.	10.7	723
246	Centrosome amplification and clonal evolution in multiple myeloma: Short review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 116-121.	4.4	4
247	Monoclonal antibodies – A new era in the treatment of multiple myeloma. <i>Blood Reviews</i> , 2016, 30, 101-110.	5.7	43
248	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 242-242.	1.4	26
249	Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3332-3332.	1.4	1
250	Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. <i>Blood</i> , 2016, 128, 3333-3333.	1.4	3
251	Predictors of Overall Survival (OS) in Patients with Multiple Myeloma (MM) Initiating First- and Second-Line Treatment in the Czech Republic. <i>Blood</i> , 2016, 128, 3607-3607.	1.4	5
252	Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse. <i>Blood</i> , 2016, 128, 5653-5653.	1.4	3

#	ARTICLE	IF	CITATIONS
253	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	1.4	37
254	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 673-673.	1.4	29
255	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8000-8000.	1.6	52
256	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 78605-78618.	1.8	6
257	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8045-8045.	1.6	1
258	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	1.4	0
259	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. <i>Blood</i> , 2016, 128, 2072-2072.	1.4	1
260	Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma. <i>Blood</i> , 2016, 128, 2073-2073.	1.4	1
261	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Blood</i> , 2016, 128, 995-995.	1.4	0
262	European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib. <i>Blood</i> , 2016, 128, 3331-3331.	1.4	0
263	The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2016, 128, 2418-2418.	1.4	1
264	Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression. <i>Blood</i> , 2016, 128, 5639-5639.	1.4	1
265	Plasma cell leukemia: from biology to treatment. <i>European Journal of Haematology</i> , 2015, 95, 16-26.	2.2	37
266	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	2.5	26
267	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
268	MicroRNAs in urine are not biomarkers of multiple myeloma. <i>Journal of Negative Results in BioMedicine</i> , 2015, 14, 16.	1.4	4
269	Immunoparesis in MGUS – Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. <i>Neoplasma</i> , 2015, 62, 827-832.	1.6	8
270	Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. <i>PLoS ONE</i> , 2015, 10, e0123866.	2.5	32

#	ARTICLE	IF	CITATIONS
271	Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS ONE, 2015, 10, e0137294.	2.5	16
272	Shared structural features of the 9aaTAD family in complex with CBP. Molecular BioSystems, 2015, 11, 844-851.	2.9	21
273	Analysis of B-Cell Subpopulations in Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e61-e71.	0.4	5
274	Flow cytometry in immunoglobulin light chain amyloidosis: Short review. Leukemia Research, 2015, 39, 1131-1136.	0.8	10
275	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	3.5	289
276	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	1.6	138
277	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. Journal of Molecular Diagnostics, 2015, 17, 652-660.	2.8	115
278	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1617-1629.	10.7	289
279	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e93.	0.4	0
280	Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. American Journal of Hematology, 2015, 90, E51-2.	4.1	8
281	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2015, 372, 142-152.	27.0	1,144
282	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. Blood, 2015, 126, 1844-1844.	1.4	5
283	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenström's Macroglobulinemia. Blood, 2015, 126, 2096-2096.	1.4	3
284	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). Blood, 2015, 126, 30-30.	1.4	8
285	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250.	1.4	27
286	Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. Blood, 2015, 126, 4514-4514.	1.4	11
287	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). Blood, 2015, 126, 729-729.	1.4	3
288	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). Blood, 2015, 126, 731-731.	1.4	8

#	ARTICLE	IF	CITATIONS
289	Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8509-8509.	1.6	14
290	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8525-8525.	1.6	2
291	Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 554-561.	0.6	1
292	The miR-29 family in hematological malignancies. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 184-191.	0.6	20
293	Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 288-293.	0.6	10
294	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 1974-1974.	1.4	0
295	Copy Number Variants Modulation and Their Clinical Impact in Multiple Myeloma. <i>Blood</i> , 2015, 126, 5304-5304.	1.4	0
296	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 927-927.	1.4	2
297	Incidence of cytogenetic aberrations in two Bâ€lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH. <i>Neoplasma</i> , 2014, 61, 48-55.	1.6	0
298	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	3.5	124
299	Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	23
300	Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014, 99, 511-518.	3.5	94
301	Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged â‰¥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. <i>Leukemia and Lymphoma</i> , 2014, 55, 1489-1497.	1.3	37
302	Flow cytometry-based enumeration and functional characterization of cd8 t regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. , 2014, 86, 220-228.		10
303	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
304	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	3.5	185
305	Nestin expression throughout multistep pathogenesis of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 164, 701-709.	2.5	15
306	New Approaches to Management of Multiple Myeloma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 157-170.	3.0	19

#	ARTICLE	IF	CITATIONS
307	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
308	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-992.	7.2	162
309	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 11-18.	1.3	4
310	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
311	High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 24-30.	0.4	8
312	Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 947-961.	3.6	144
313	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
314	Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. <i>Haematologica</i> , 2014, 99, 360-364.	3.5	133
315	Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. <i>Blood</i> , 2014, 124, 198-198.	1.4	3
316	Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. <i>Blood</i> , 2014, 124, 2043-2043.	1.4	3
317	Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]. <i>Blood</i> , 2014, 124, 2071-2071.	1.4	9
318	Somatic Mutation Spectrum in Monoclonal Gammopathy of Undetermined Significance Compared to Multiple Myeloma. <i>Blood</i> , 2014, 124, 3346-3346.	1.4	1
319	Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic. <i>Blood</i> , 2014, 124, 3376-3376.	1.4	1
320	Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3423-3423.	1.4	5
321	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). <i>Blood</i> , 2014, 124, 5682-5682.	1.4	1
322	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	1.4	15
323	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	1.4	0
324	Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group. <i>Blood</i> , 2014, 124, 2117-2117.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3448-3448.	1.4	1
326	Does AL Amyloidosis Have Unique Gene Expression Profile? Meta-Analysis Results. <i>Blood</i> , 2014, 124, 5689-5689.	1.4	0
327	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. <i>Hematological Oncology</i> , 2013, 31, 41-48.	1.7	39
328	Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. <i>Journal of Translational Medicine</i> , 2013, 11, 77.	4.4	23
329	Serum miR-29a as a marker of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 189-191.	1.3	44
330	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2013, 37, 829-837.	0.8	48
331	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 247-255.	1.6	69
332	Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. <i>Leukemia and Lymphoma</i> , 2013, 54, 1324-1326.	1.3	19
333	Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. <i>Genomics</i> , 2013, 102, 243-249.	2.9	15
334	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	10.7	219
335	Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 551-564.	2.5	74
336	Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 123-130.	0.4	20
337	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. <i>Leukemia Research</i> , 2013, 37, 1063-1069.	0.8	3
338	Molecular heterogeneity and centrosome-associated genes in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1982-1988.	1.3	6
339	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.	7.2	294
340	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	7.2	174
341	Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. <i>Haematologica</i> , 2013, 98, 784-788.	3.5	57
342	Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. <i>Acta Oncologica</i> , 2013, 52, 994-1001.	1.8	16

#	ARTICLE	IF	CITATIONS
343	Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. <i>Oncolimmunology</i> , 2013, 2, e25619.	4.6	14
344	Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. , 2013, , n/a-n/a.		8
345	Heterogeneity and Plasticity of Multiple Myeloma. , 2013, , .		0
346	Cell Cycle Gene Sets Coordination In Multiple Myeloma and Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 1901-1901.	1.4	1
347	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethasone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	1.4	13
348	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	1.4	20
349	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	1.6	6
350	Genome Wide Profiling Of Chromosomal Abnormalities In 37 Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS). <i>Blood</i> , 2013, 122, 1874-1874.	1.4	0
351	Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. <i>Acta Oncologica</i> , 2012, 51, 412-415.	1.8	15
352	Lenalidomide: a new treatment option for Castleman disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 2089-2091.	1.3	14
353	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2475-2482.	1.6	185
354	Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 920-927.	1.3	36
355	Cytokine analysis in a patient with relapsing Kikuchi's Fujimoto disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 743-745.	1.3	5
356	Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1406-1408.	1.3	30
357	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. <i>Haematologica</i> , 2012, 97, 784-791.	3.5	49
358	Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. <i>Nuclear Medicine and Biology</i> , 2012, 39, 429-436.	0.6	13
359	Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R) Tj ETQq1 1 0.784314 rg33 /Overbo		
360	TGF-β2 "an excellent servant but a bad master. <i>Journal of Translational Medicine</i> , 2012, 10, 183.	4.4	390

#	ARTICLE	IF	CITATIONS
361	Bone marrow plasma cell separation – validation of separation algorithm. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1139-40.	2.3	7
362	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
363	Myeloma Genetics International Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 796-800.	1.3	7
364	Mechanism of immunomodulatory drugs in multiple myeloma. <i>Leukemia Research</i> , 2012, 36, 1218-1224.	0.8	23
365	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. <i>Leukemia and Lymphoma</i> , 2012, 53, 2500-2503.	1.3	10
366	Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e47077.	2.5	101
367	Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment. <i>PLoS ONE</i> , 2012, 7, e49446.	2.5	40
368	Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results. <i>Neoplasma</i> , 2012, 59, 440-449.	1.6	26
369	Regulatory Cells and Multiple Myeloma. , 2012, , .		1
370	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1759-1769.	27.0	692
371	High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group. <i>Blood</i> , 2012, 120, 4528-4528.	1.4	0
372	Extramedullary Relapse of Multiple Myeloma - Plasma Cells Characteristics.. <i>Blood</i> , 2012, 120, 2935-2935.	1.4	0
373	Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 414-420.	0.4	10
374	Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 517-520.	0.4	16
375	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.	0.4	38
376	Association of aneuploidy category with centrosome amplification in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2020-2022.	1.3	3
377	Prognostic significance of morphological assessment of plasma cells in multiple myeloma. <i>Neoplasma</i> , 2011, 58, 554-560.	1.6	6
378	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285

#	ARTICLE	IF	CITATIONS
379	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	1.4	309
380	Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 1441-1447.	1.8	4
381	Proteomic Analysis in Multiple Myeloma Research. <i>Molecular Biotechnology</i> , 2011, 47, 83-93.	2.4	15
382	The problems of proteinuria measurement in urine with presence of Bence Jones protein. <i>Clinical Biochemistry</i> , 2011, 44, 403-405.	1.9	6
383	Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients. <i>Leukemia Research</i> , 2011, 35, 1008-1013.	0.8	13
384	Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. <i>Haematologica</i> , 2011, 96, 1728-1732.	3.5	48
385	Interlaboratory study of free monoclonal immunoglobulin light chain quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 89-92.	2.3	7
386	Successful Anakinra Therapy in 2 Patients with Schnitzler Syndrome. <i>Onkologie</i> , 2011, 34, 265-268.	0.8	7
387	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. <i>Leukemia</i> , 2011, 25, 749-760.	7.2	108
388	Regulatory T Cells Predicts Progression in Previously Untreated Myeloma Patients and Treatment by Cyclophosphamide, Thalidomide Plus Dexamethasone Reduces Regulatory T Cells. <i>Blood</i> , 2011, 118, 2870-2870.	1.4	3
389	Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens. <i>Blood</i> , 2011, 118, 2874-2874.	1.4	1
390	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients \geq 65 Years. <i>Blood</i> , 2011, 118, 3988-3988.	1.4	2
391	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) \geq 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011, 118, 475-475.	1.4	12
392	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , 2011, 118, 811-811.	1.4	16
393	Centrosomal Disruption As Early Event in Myeloma Development. <i>Blood</i> , 2011, 118, 1806-1806.	1.4	9
394	Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. <i>Haematologica</i> , 2010, 95, 1548-1554.	3.5	75
395	Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. <i>Annals of Hematology</i> , 2010, 89, 385-389.	1.8	29
396	Salvage treatment with upfront melphalan 100 mg/m ² and consolidation with novel drugs for fulminant progression of multiple myeloma. <i>Annals of Hematology</i> , 2010, 89, 483-487.	1.8	6

#	ARTICLE	IF	CITATIONS
397	IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 311-314.	1.9	11
398	Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. <i>International Journal of Hematology</i> , 2010, 92, 314-319.	1.6	26
399	Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma. <i>Leukemia Research</i> , 2010, 34, 1007-1011.	0.8	13
400	Individual myeloma-specific T cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2010, 148, 859-867.	2.5	10
401	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. <i>British Journal of Haematology</i> , 2010, 149, 334-351.	2.5	88
402	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. <i>Leukemia</i> , 2010, 24, 1700-1712.	7.2	76
403	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <i>Leukemia</i> , 2010, 24, 1121-1127.	7.2	677
404	Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. <i>Neoplasma</i> , 2010, 57, 111-117.	1.6	17
405	Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- driven nonapeptides or myeloma cell apoptotic bodies. <i>Neoplasma</i> , 2010, 57, 455-464.	1.6	20
406	Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. <i>Neoplasma</i> , 2010, 57, 29-34.	1.6	28
407	Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors. <i>Neoplasma</i> , 2010, 57, 482-487.	1.6	15
408	Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Thyroid</i> , 2010, 20, 1209-1214.	4.5	61
409	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	1.3	14
410	Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 548-554.	2.0	59
411	Light Chain-Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4635-4641.	1.6	133
412	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	1.3	49
413	Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 3065-3065.	1.4	8
414	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens. <i>Blood</i> , 2010, 116, 622-622.	1.4	30

#	ARTICLE	IF	CITATIONS
415	Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).. Journal of Clinical Oncology, 2010, 28, 8133-8133.	1.6	1
416	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients. Blood, 2010, 116, 1939-1939.	1.4	0
417	Flow Cytometric Phenotyping and Analysis of CD8 Regulatory and Suppressor Cells In Multiple Myeloma. Blood, 2010, 116, 2947-2947.	1.4	1
418	Association Study of Ploidy Category with Mitotic Disruption In Multiple Myeloma. Blood, 2010, 116, 2952-2952.	1.4	0
419	Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma. Neoplasma, 2009, 56, 404-413.	1.6	11
420	Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma, 2009, 56, 526-532.	1.6	14
421	Chromatin Structure and Epigenetics of Tumour Cells: A Review. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 51-61.	0.7	4
422	Interdigitating Dendritic Cell Sarcoma of the Leg. Onkologie, 2009, 32, 364-365.	0.8	8
423	Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer. American Journal of Epidemiology, 2009, 169, 1463-1470.	3.4	43
424	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 2009, 23, 215-224.	7.2	686
425	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia, 2009, 23, 1716-1730.	7.2	136
426	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 2009, 23, 1904-1912.	7.2	207
427	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia, 2009, 23, 1545-1556.	7.2	428
428	Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation. Leukemia Research, 2009, 33, 1490-1498.	0.8	16
429	Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib. Clinical Lymphoma and Myeloma, 2009, 9, 151-153.	1.4	40
430	Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse. Clinical Lymphoma and Myeloma, 2009, 9, 436-442.	1.4	11
431	<i>In vitro</i> activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. Journal of Immunotoxicology, 2009, 6, 243-248.	1.7	5
432	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 2009, 113, 3435-3442.	1.4	213

#	ARTICLE	IF	CITATIONS
433	Flow Cytometric Phenotyping and Analysis of T Regulatory Cells in Monoclonal Gammopathy Patients.. Blood, 2009, 114, 2819-2819.	1.4	8
434	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 2008, 112, 1529-1537.	4.1	68
435	Nuclear organization of PML bodies in leukaemic and multiple myeloma cells. Leukemia Research, 2008, 32, 1866-1877.	0.8	19
436	The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia, 2008, 22, 1479-1484.	7.2	65
437	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplantation, 2008, 41, 51-54.	2.4	19
438	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. Clinical Lymphoma and Myeloma, 2008, 8, 352-355.	1.4	54
439	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	27.0	1,787
440	Capillary immunotyping electrophoresis and high resolution two-dimensional electrophoresis for the detection of κ 4-heavy chain disease. Clinica Chimica Acta, 2008, 389, 171-173.	1.1	4
441	The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency. Journal of Clinical Oncology, 2008, 26, 8562-8562.	1.6	0
442	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. Journal of Clinical Oncology, 2007, 25, 3892-3901.	1.6	607
443	Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma. Journal of Immunology, 2007, 178, 6789-6795.	0.8	9
444	O58 Correlation between chromosomal aberrations and standard prognostic factors in patients with multiple myeloma undergoing autologous stem cell transplantation. Blood Reviews, 2007, 21, S85.	5.7	0
445	P141 Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?. Blood Reviews, 2007, 21, S131.	5.7	0
446	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology, 2007, 79, 305-309.	2.2	9
447	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. Blood, 2007, 110, 2735-2735.	1.4	1
448	Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.. Blood, 2007, 110, 3603-3603.	1.4	10
449	Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.. Blood, 2007, 110, 529-529.	1.4	17
450	Expression of MAGE-A1 and MAGE-A3 in Bone Marrow from Monoclonal Gammopathy to Myeloma Patients.. Blood, 2007, 110, 4752-4752.	1.4	0

#	ARTICLE	IF	CITATIONS
451	Phenotypic Analysis of Plasma Cells in Monoclonal Gammopathy and Multiple Myeloma Subjects.. Blood, 2007, 110, 4755-4755.	1.4	0
452	Low Molecular Weight Heparin in Sufficient Dose of 70 IU/kg as an Effective and Safe Thromboprophylaxis in Patients with Newly Diagnosed Multiple Myeloma during Conventional VAD Induction Therapy.. Blood, 2007, 110, 2732-2732.	1.4	0
453	Isolation and Expansion of Allogeneic Myeloma-Specific Interferon-Gamma Producing T Cells for Adoptive Immunotherapy. Medical Oncology, 2006, 23, 377-384.	2.5	5
454	Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplantation, 2005, 35, 159-164.	2.4	41
455	Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. The Hematology Journal, 2005, 5, 559-564.	1.4	10
456	Monitoring of Dendritic Cell Numbers in Patients during the Treatment of Multiple Myeloma.. Blood, 2005, 106, 5096-5096.	1.4	0
457	Identification and Expansion of Myeloma-Specific Cytotoxic T Cells In Vitro.. Blood, 2005, 106, 5138-5138.	1.4	0
458	Second Autologous Transplantation for Multiple Myeloma Patients Relapsing after the First Autograft – a Pilot Study for the Evaluation of Experimental Maintenance Therapies. Report of the Prospective Non-Randomized Pilot Study of the Czech Myeloma Group. Oncology Research and Treatment, 2004, 27, 275-279.	1.2	14
459	Angiotensin-I Converting Enzyme Inhibitors and the Survival of Patients with Multiple Myeloma Treated by Autologous Stem Cell Transplantation.. Blood, 2004, 104, 944-944.	1.4	0
460	Treatment of Chronic Myeloid Leukemia with Autologous. Medical Oncology, 2003, 20, 69-76.	2.5	3
461	Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine, 2003, 21, 877-882.	3.8	12
462	Dendritic Cell-based Immunotherapy for the Treatment of Hematological Malignancies. Hematology, 2003, 8, 97-104.	1.5	18
463	Interleukin-2 Activation of Haematopoietic Stem Cells. Vienna Clinical Weekly, 2002, 29, 61-67.	0.9	2
464	Dendritic Cell Vaccines in the Treatment of Multiple Myeloma : Advances and Limitations. Medical Oncology, 2002, 19, 213-218.	2.5	10
465	Bone Mineral Density in Multiple Myeloma Patients after Intravenous Clodronate Therapy. Vienna Clinical Weekly, 2001, 28, 38-42.	0.9	2
466	Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Medical Oncology, 2000, 17, 2-15.	2.5	53
467	Sepsis and septic shock. Supportive Care in Cancer, 1995, 3, 106-110.	2.2	9
468	Sepsis and septic shock. Supportive Care in Cancer, 1995, 3, 111-119.	2.2	5

#	ARTICLE	IF	CITATIONS
469	Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. , 0, , .		0
470	Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies. , 0, , .		4